Vasopressin-receptor research peptide (CHEMBL1817752)
A small experimental peptide that switches on vasopressin and oxytocin receptors; used only as a lab research tool, never tested in people.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
CHEMBL1817752 is an experimental 8-residue peptide (sequence CFINNCPG) developed as part of a medicinal-chemistry effort to build short-acting peptidic agonists at vasopressin-family receptors (Wiśniewski 2011). It is a research compound — characterized in a published bioassay, catalogued in ChEMBL, but never a clinical drug. The two cysteines in its sequence mirror the cyclic scaffold used by native vasopressin and oxytocin, where a disulfide bridge between the two cysteines defines the binding ring.
On this platform the card lists the V1a receptor (AVPR1A) as the primary target, with V1b (AVPR1B) and the oxytocin receptor (OXTR) as secondary annotations. The reported potency in the card's structured metadata is EC50 = 3700 nM (ChEMBL CHEMBL1817752) — a modest, micromolar-range activity characteristic of an early SAR series rather than an optimised lead.
What it does
In the assay context reported by Wiśniewski and colleagues (2011), this scaffold acts as a peptidic agonist at the V1a vasopressin receptor — meaning, when it engages V1a, it triggers the same downstream signalling that native vasopressin does at that receptor (vascular smooth muscle contraction in physiological tissue). The "short-acting" framing in the paper title is the key design intent: the series was built to retain V1a agonist activity while degrading quickly in plasma, giving a more controllable pharmacological profile than the long-lived native hormone.
This particular 8-mer is one member of that exploratory series. With a reported EC50 in the low-micromolar range it is far weaker than native vasopressin, and there is no published evidence that CHEMBL1817752 itself was advanced beyond bench characterization.
Evidence
- Human: No human data. This is a research compound; no clinical or human-tissue studies are published for CHEMBL1817752 specifically.
- Animal: No in-vivo data identified in the dossier for this specific analog.
- In vitro: Receptor-binding / functional characterization in the Wiśniewski (2011) SAR series, with EC50 = 3700 nM recorded in ChEMBL under accession CHEMBL1817752.
Related peptides
This card sits inside the vasopressin scaffold family — small cyclic peptides built on a two-cysteine ring, varying in side-chain identity to tune receptor selectivity and pharmacokinetics:
- Vasopressin (/card/pep-04423) — the endogenous nonapeptide and reference compound for V1a, V1b, and V2 activity.
- Desmopressin (/card/pep-10872) — the V2-selective vasopressin analog used clinically for diabetes insipidus and bedwetting.
- Oxytocin (/card/pep-04424) — the sister nonapeptide, differing from vasopressin at two positions, with its own dedicated receptor.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| EC50 | 3700 nM | GPCRDB/ChEMBL |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10299,
sequence = {CFINNCPG},
target = {avpr1a},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}